Texas Permanent School Fund Corp Sells 29,230 Shares of Roivant Sciences Ltd. $ROIV

Texas Permanent School Fund Corp trimmed its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 10.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 247,742 shares of the company’s stock after selling 29,230 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Roivant Sciences were worth $2,792,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Amundi increased its stake in Roivant Sciences by 18.1% during the 1st quarter. Amundi now owns 398,729 shares of the company’s stock worth $3,991,000 after acquiring an additional 61,214 shares during the period. Inspire Investing LLC bought a new stake in shares of Roivant Sciences during the 1st quarter valued at $303,000. IFG Advisory LLC acquired a new stake in shares of Roivant Sciences during the 2nd quarter worth $255,000. Valeo Financial Advisors LLC bought a new position in shares of Roivant Sciences in the second quarter worth $1,145,000. Finally, Franklin Resources Inc. acquired a new position in Roivant Sciences in the second quarter valued at about $997,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $22.41 on Friday. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $23.47. The firm has a market capitalization of $15.59 billion, a P/E ratio of -40.02 and a beta of 1.22. The company’s 50 day moving average price is $20.00 and its two-hundred day moving average price is $15.10.

Insider Transactions at Roivant Sciences

In related news, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68. Following the sale, the insider owned 36,350,621 shares of the company’s stock, valued at $798,259,637.16. This trade represents a 5.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Matthew Gline sold 1,740,000 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $21.68, for a total value of $37,723,200.00. Following the completion of the transaction, the chief executive officer directly owned 17,290,820 shares of the company’s stock, valued at approximately $374,864,977.60. The trade was a 9.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 12,789,184 shares of company stock valued at $260,400,767 over the last quarter. 10.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. The Goldman Sachs Group raised their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. JPMorgan Chase & Co. boosted their price objective on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. Leerink Partners upped their target price on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Citigroup lifted their price target on Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Guggenheim reissued a “buy” rating and set a $28.00 price target on shares of Roivant Sciences in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.19.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.